Posted on 31/01/08
Ottawa moves to reduce price of drug after cancer patients complain of gouging
A cancer drug will be subject to retroactive price controls after its cost to patients jumped almost ninefold - to as much as $4,200 a month.The Patented Medicine Prices Review Board ruled that it has jurisdiction over the multiple myeloma drug thalidomide and can regulate its cost.
The full text of this article has 1093 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
